Literature DB >> 12372956

Salvage of cyclosporine A-induced oxidative stress and renal dysfunction by carvedilol.

Satyanarayana S V Padi1, Kanwaljit Chopra.   

Abstract

BACKGROUND: Cyclosporine A (CsA) is the first-line immunosuppressant employed for the management of solid organ transplantation and autoimmune diseases. Nephrotoxicity is the major limitation of CsA use. Recent evidence suggests that reactive oxygen species (ROS) play an important role in mediating CsA nephrotoxicity. The present study was designed to investigate effects of carvedilol, a third-generation beta-blocker with potent free radical-scavenging activity on CsA-induced oxidative stress and resultant renal dysfunction in a rat model of chronic CsA nephrotoxicity.
METHODS: Carvedilol (2.0 and 4.0 mg/kg i.p.) and propranolol (10 mg/kg i.p.) were administered to separate group of animals 24 h before and concurrently with CsA (20 mg/kg s.c.) for 21 days. Renal function was assessed by estimating plasma creatinine, blood urea nitrogen (BUN), creatinine and urea clearance. Tissue lipid peroxidation was measured as thiobarbituric acid-reacting substances (TBARS). Renal morphological alterations were assessed by histopathological examination of hematoxylin-eosin, PAS and Masson's trichrome stained sections of the kidneys.
RESULTS: CsA (20 mg/kg s.c) administration for 21 days produced elevated levels of TBARS and deteriorated renal function as assessed by increased plasma creatinine, BUN and decreased creatinine and urea clearance as compared to vehicle-treated rats. The kidneys of CsA-treated rats showed severe striped interstitial fibrosis, arteriolopathy, glomerular basement thickening, tubular vacuolization and hyaline casts. Propranolol neither decreased TBARS nor improved the renal dysfunction and morphological changes induced by CsA. Both doses of carvedilol markedly reduced elevated levels of TBARS, whereas the higher dose of carvedilol significantly attenuated renal dysfunction and morphological changes in CsA-treated rats.
CONCLUSIONS: These data clearly indicate the renoprotective potential of carvedilol in CsA-induced nephrotoxicity and suggest a significant contribution of its antilipoperoxidative property in this beneficial effect. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12372956     DOI: 10.1159/000064095

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  9 in total

1.  Evolutionarily conserved role of calcineurin in phosphodegron-dependent degradation of phosphodiesterase 4D.

Authors:  Hong Zhu; Hee Yun Suk; Raymond Y L Yu; Deborah Brancho; Opeyemi Olabisi; Teddy T C Yang; XiaoYong Yang; Jialin Zhang; Mustapha Moussaif; Jorge L Durand; Linda A Jelicks; Ja-Young Kim; Philipp E Scherer; Philippe G Frank; Michael P Lisanti; John W Calvert; Mark R Duranski; David J Lefer; Elaine Huston; George S Baillie; Miles D Houslay; Jeffrey D Molkentin; Jianping Jin; Chi-Wing Chow
Journal:  Mol Cell Biol       Date:  2010-07-20       Impact factor: 4.272

2.  The epoxyeicosatrienoic acid analog PVPA ameliorates cyclosporine-induced hypertension and renal injury in rats.

Authors:  Michael M Yeboah; Md Abdul Hye Khan; Marla A Chesnik; Amit Sharma; Mahesh P Paudyal; John R Falck; John D Imig
Journal:  Am J Physiol Renal Physiol       Date:  2016-06-29

3.  Provinol prevents CsA-induced nephrotoxicity by reducing reactive oxygen species, iNOS, and NF-kB expression.

Authors:  Barbara Buffoli; Olga Pechánová; Stanislava Kojsová; Ramaroson Andriantsitohaina; Lorena Giugno; Rossella Bianchi; Rita Rezzani
Journal:  J Histochem Cytochem       Date:  2005-06-13       Impact factor: 2.479

4.  Effect of carvedilol on behavioral, mitochondrial dysfunction, and oxidative damage against D-galactose induced senescence in mice.

Authors:  Anil Kumar; Samrita Dogra; Atish Prakash
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-08-15       Impact factor: 3.000

5.  Antihypertensive activity, toxicity and molecular docking study of newly synthesized xanthon derivatives (xanthonoxypropanolamine).

Authors:  Omprakash Goshain; Bahar Ahmed
Journal:  PLoS One       Date:  2019-08-15       Impact factor: 3.240

Review 6.  Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction.

Authors:  William H Frishman; Linda S Henderson; Mary Ann Lukas
Journal:  Vasc Health Risk Manag       Date:  2008

Review 7.  Established and newly proposed mechanisms of chronic cyclosporine nephropathy.

Authors:  Hye Eun Yoon; Chul Woo Yang
Journal:  Korean J Intern Med       Date:  2009-06-08       Impact factor: 2.884

Review 8.  Mitochondria: a new therapeutic target in chronic kidney disease.

Authors:  Simona Granata; Alessandra Dalla Gassa; Paola Tomei; Antonio Lupo; Gianluigi Zaza
Journal:  Nutr Metab (Lond)       Date:  2015-11-25       Impact factor: 4.169

9.  Effect of a Low Dose of Carvedilol on Cyclophosphamide-Induced Urinary Toxicity in Rats-A Comparison with Mesna.

Authors:  Anna Merwid-Ląd; Piotr Ziółkowski; Marta Szandruk-Bender; Agnieszka Matuszewska; Adam Szeląg; Małgorzata Trocha
Journal:  Pharmaceuticals (Basel)       Date:  2021-11-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.